Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleFocus: Healthcare Reform and Laboratory Reimbursement

Current Status of Clinical Laboratory Reimbursement

Rick Panning
American Society for Clinical Laboratory Science April 2014, 27 (2) 119-126; DOI: https://doi.org/10.29074/ascls.27.2.119
Rick Panning
Chair, ASCLS Government Affairs Committee , Director of Business Development for Shared Clinical Services, Fairview Health Services, Minneapolis, MN
CM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: panning4@comcast.net
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. Rick Panning, MBA, MLS(ASCP)CM⇑
    1. Chair, ASCLS Government Affairs Committee , Director of Business Development for Shared Clinical Services, Fairview Health Services, Minneapolis, MN
  1. Address for Correspondence: Rick Panning, MBA, MLS(ASCP)CM, 4894 Meadow Lane, Shoreview, MN 55126, 651-280-5909, panning4{at}comcast.net.
  1. Define the basic difference between retrospective reimbursement and prospective payment as it applies to laboratory services. Describe the impact this has had on the laboratory.

  2. Describe how ACA has specifically impacted laboratory reimbursement in at least two ways.

  3. Identify current potential threats to laboratory reimbursement.

Extract

Introduction In general, reimbursement for laboratory services in this country comes from two third-party payer sources - government and private sector. This third-party payment allows patients to access laboratory services from hospitals, physician offices, long-term care and other post acute providers and private laboratories. There are many components to this complex reimbursement system, including how and when tests are covered (coverage decisions), procedure and diagnosis codes (identifying what was actually ordered and performed) and payment methodologies. While levels of reimbursement are intended to reflect the value and the cost of the service being provided, over time the level of payment has been continually reduced to meet financial goals of the government or the healthcare system.

Government payers primarily reflect Medicare on the federal level and Medicaid (Medical Assistance) on the state level. The Medicare program is the most influential reimbursement system since it often impacts state programs and private payer reimbursement policies and payment levels. All public payers and approximately 67% of private payers use Medicare's payment methodologies as the basis for their own and as tools for negotiating discounts with providers.1 In our current fiscal environment, with pressures on the federal budget and concerns about the long term viability of Medicare, we have seen a change in which the Medicare program is beginning to look at private payer reimbursement levels as an opportunity to reduce its financial responsibility for laboratory reimbursement.

The steady reduction in payment levels from Medicare and other payers are resulting in a negative impact on…

ABBREVIATIONS: ACA – Accountable Care Act; APC – Ambulatory Patient Classification; CAH – Critical Access Hospital; CLFS – Clinical Laboratory Fee Schedule; CMS – Centers for Medicare and Medicaid Services; CPI – Consumer Price Index; DRG – Diagnosis Related Group; FEHB – Federal Employee Health Benefits; IOM – Institute of Medicine; MolDX – Molecular Diagnostics; MS-DRG – Medical Severity Diagnosis Related Group; NLA – National Limitation Amount; OIG – Office of Inspector General; OPPS – Outpatient Prospective Payment System; PPS – Prospective Payment System; SGR – Sustainable Growth Rate.

    INDEX TERMS
  • Clinical Laboratory Reimbursement
  • Clinical Laboratory Fee Schedule
  • Fee-for-Service
  • Diagnosis Related Group
  • Prospective Payment System
  • Sustainable Growth Rate
  • Competitive Bidding
  • Laboratory Copayment
  • OPPS Bundling
  1. Define the basic difference between retrospective reimbursement and prospective payment as it applies to laboratory services. Describe the impact this has had on the laboratory.

  2. Describe how ACA has specifically impacted laboratory reimbursement in at least two ways.

  3. Identify current potential threats to laboratory reimbursement.

  • © Copyright 2014 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 27 (2)
American Society for Clinical Laboratory Science
Vol. 27, Issue 2
Spring 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Current Status of Clinical Laboratory Reimbursement
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Current Status of Clinical Laboratory Reimbursement
Rick Panning
American Society for Clinical Laboratory Science Apr 2014, 27 (2) 119-126; DOI: 10.29074/ascls.27.2.119

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Current Status of Clinical Laboratory Reimbursement
Rick Panning
American Society for Clinical Laboratory Science Apr 2014, 27 (2) 119-126; DOI: 10.29074/ascls.27.2.119
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Accountable Care Organizations: An Integrated Model of Patient Care Objectives
  • Introduction
Show more Focus: Healthcare Reform and Laboratory Reimbursement

Similar Articles

Keywords

  • Clinical Laboratory Reimbursement
  • Clinical Laboratory Fee Schedule
  • Fee-for-Service
  • Diagnosis Related Group
  • Prospective Payment System
  • Sustainable Growth Rate
  • Competitive Bidding
  • Laboratory Copayment
  • OPPS Bundling

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire